Ajanta Pharma has disclosed that promoter Aayush Agrawal has pledged 1,49,000 shares of the company to enhance loan facilities. The pledge creation was formally communicated to BSE and NSE on February 13, 2026, in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Transaction Details

The pledge was created on February 11, 2026, with Bajaj Financial Securities Ltd serving as the beneficiary entity. Aayush Agrawal, acting as trustee of Aayush Agrawal Trust, cited loan increase as the primary reason for this encumbrance.

Impact on Shareholding Pattern

Following this pledge creation, Aayush Agrawal's total encumbered shareholding has increased significantly. The transaction has raised his total pledged shares from 80,99,407 to 82,48,407 shares.

Promoter Group Holdings

The disclosure also provided a comprehensive overview of the entire promoter group's shareholding pattern. Other significant promoters include Yogesh M Agrawal and Rajesh M Agrawal, each holding 14.47% of the company's share capital through their respective trusts.

Key promoter holdings include:

• Yogesh M Agrawal Trust: 1,80,78,147 shares (14.47%)
• Rajesh M Agrawal Trust: 1,80,78,148 shares (14.47%)
• Ravi P Agrawal Trust: 1,62,42,904 shares (13.00%)
• Gabs Investments Pvt Ltd: 1,25,88,393 shares (10.08%)

Regulatory Compliance

The pledge disclosure was made in accordance with Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. The formal communication was addressed to both BSE and NSE, with copies provided to the company secretary of Ajanta Pharma Limited. This transaction represents a standard corporate financing arrangement where promoter shares serve as collateral for enhanced borrowing facilities.

Ajanta Pharma has issued a formal clarification to stock exchanges denying its involvement in the acquisition of Restaurant Brands Asia, following incorrect media reports that suggested the pharmaceutical company was diversifying into the restaurant business.

Clarification on Media Reports

The company addressed reports published in The Economic Times on February 10, 2026, which incorrectly stated that "the transaction would mark the drugmaker's diversification into the fast-growing quick service restaurant sector." Ajanta Pharma emphasized that this reference was factually incorrect and inadvertent.

Actual Transaction Details

The pharmaceutical company clarified the true nature of the acquisition:

Company's Position

Ajanta Pharma stated that while a section of its promoter group manages and controls Lenexis Foodworks Pvt. Ltd., which is independently pursuing the Restaurant Brands Asia acquisition, Ajanta Pharma Limited and its management are not parties to the transaction in any manner. The company explicitly denied the rumors and speculation circulating regarding its involvement.

Regulatory Compliance

The clarification was submitted under Regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced a similar clarification it had submitted to stock exchanges on January 20, 2026, following earlier media reports on the same matter.

Communication to Exchanges

The formal clarification was signed by Gaurang Shah, Senior Vice President – Legal & Company Secretary, and submitted to both BSE Limited and National Stock Exchange of India on February 10, 2026. The company requested the exchanges to take the clarification on record and disseminate it to all concerned parties.